Recursion Pharmaceuticals LLC has described molecular glue degraders comprising DDB1- and CUL4-associated factor 15 (DCAF15) and RNA-binding protein 39 (RBM39) protein acting as RBM39 degradation inducers and RBM39/DCAF15 interaction inducers reported to be useful for the treatment of renal cell carcinoma.
The artificial intelligence company Recursion Pharmaceuticals Inc. and Bayer AG have upped the ante on their 2020 collaboration deal to include precision oncology, with the possibility of more than $1 billion in potential milestone payments for Recursion.
Rapidly evolving artificial intelligence (AI) is effectively resetting all biopharmaceutical companies to the figurative starting line, and collaboration is a key strategy to winning the drug discovery race, an AI-based startup founder said at the Global Bio Conference (GBC) 2023.
Rapidly evolving artificial intelligence (AI) is effectively resetting all biopharmaceutical companies to the figurative starting line, and collaboration is a key strategy to winning the drug discovery race, an AI-based startup founder said at the Global Bio Conference (GBC) 2023.
The pace at which companies are integrating the sophisticated tools of artificial intelligence (AI) and machine learning (ML) into their drug discovery and development programs continues to accelerate.
Recursion Pharmaceuticals Inc. priced its IPO at a level that, with anticipated gross proceeds of $436.4 million, would make it 2021’s second largest biopharma IPO and the eighth largest ever. Salt Lake City-based Recursion’s shares (NASDAQ:RXRX) were priced at $18 each when the market opened and closed April 16’s trading 73.89% higher at $31.30 each.